Filing Flows

Filing Flows › Health Care › Prothena Corp Public (PRTA)

Prothena Corp Public (PRTA) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Prothena Corp Public (PRTA) Q3 2026 earnings results →

Q3 2026 Revenue down 74% year over year to $620K

Prothena Corp Public made $620K in Q3 2026 (-74% Y/Y). Operating margin n/m, net loss $16.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$620K
Year over year-74%
Operating marginn/m
Net earnings−$16.5M
Operating cash flow−$12.0M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $620K in Q3 2026, down 74% year over year and down 39% from the previous quarter.

Operating costs exceeded revenue by $18.8M, an operating margin of -3035.6%. Total costs fell 54% while revenue fell 74%. The quarter ended with a net loss of $16.5M, narrower than the previous quarter's $18.6M loss.

Operating cash flow was −$12.0M. Non-cash charges added back $209K of depreciation and amortization and $6.4M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $73K exceeded it, leaving free cash flow of −$12.0M.

Quarterly history

Prothena Corp Public revenue by quarterProthena Corp Public revenue by quarter$2.8MQ1 2025$4.4MQ2 2025$2.4MQ3 2025$21KQ4 2025$51.1MQ1 2026$1.0MQ2 2026$620KQ3 2026
Prothena Corp Public net earnings by quarterProthena Corp Public net earnings by quarter−$60.2MQ1 2025−$126MQ2 2025−$36.5MQ3 2025−$21.6MQ4 2025$32.7MQ1 2026−$18.6MQ2 2026−$16.5MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 5, 2026$620K-74%n/m−$16.5M−$12.0M
Q2 202610-QAug 6, 2026$1.0M-77%n/m−$18.6M−$25.0M
Q1 202610-QMay 7, 2026$51.1M18×58.8%$32.7M$28.9M
Q4 202510-KFeb 27, 2026$21K-99%n/m−$21.6M−$23.3M
Q3 202510-QNov 6, 2025$2.4M+149%n/m−$36.5M−$40.6M
Q2 202510-QAug 4, 2025$4.4M-97%n/m−$126M−$46.3M
Q1 202510-QMay 8, 2025$2.8M57×n/m−$60.2M−$53.4M

Charts

Prothena Corp Public: revenue growth, year over year and quarter over quarterProthena Corp Public: revenue growth, year over year and quarter over quarterY/YQ/Q+400%Q1 2025-97%+56%Q2 2025+149%-45%Q3 2025-99%-99%Q4 2025+400%+400%Q1 2026-77%-98%Q2 2026-74%-39%Q3 2026
Latest (Q3 2026): Y/Y -74%, Q/Q -39%.
Prothena Corp Public: where the cash came from (+) and went (−), TTM to Q3 2026Prothena Corp Public: where the cash came from (+) and went (−), TTM to Q3 2026Cash drawn (+) / kept (−)$59.5MOperating cash flow−$31.4MOther financing−$27.3MOther investing−$725K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Prothena Corp Public: profit against cash, quarter by quarterProthena Corp Public: profit against cash, quarter by quarterNet incomeOperating cash flow−$58.0M−$47.8MQ4 2024−$60.2M−$53.4MQ1 2025−$126M−$46.3MQ2 2025−$36.5M−$40.6MQ3 2025−$21.6M−$23.3MQ4 2025$32.7M$28.9MQ1 2026−$18.6M−$25.0MQ2 2026−$16.5M−$12.0MQ3 2026
Latest (Q3 2026): Net income −$16.5M, Operating cash flow −$12.0M.
Prothena Corp Public: diluted shares by fiscal yearProthena Corp Public: diluted shares by fiscal year40MFY202048MFY202147MFY202253MFY202354MFY202454MFY2025
+34.9% since FY2020: more shares outstanding (issuance, stock pay).
Prothena Corp Public in its industry: growth against margin (225 companies, SIC 2834)Prothena Corp Public in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMPRTA (-74%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Prothena Corp Public

Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases.

In its own words, from its 10-K, filed Feb 27, 2026.

Prothena Corp Public against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -74% against the peers' median +7%.

CompanyQuarterRevenueY/YOp. margin
PRTA Prothena Corp PublicQ3 2026$620K-74%n/m
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Prothena Corp Public 10-Q on SEC EDGAR · CIK 1559053 · Pharmaceutical Preparations

Guidance and outlook

Prothena Corp Public: what its forward-looking statements are about (10-Q filed 2026-11-05)Prothena Corp Public: what its forward-looking statements are about (10-Q filed 2026-11-05)Other16Backlog1Demand1
18 statements; tone +0.06 (−1 all cautious, +1 all confident); 4 hedged.
Prothena Corp Public: outlook statements against the filing beforeProthena Corp Public: outlook statements against the filing beforeConfident2Cautious1

More on PRTA

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare PRTA with

中文版：Prothena Corp Public（PRTA）财报

Español · Français